Information från ABG Sundal Collier

Här finner du information kring börsens mindre och medelstora bolag. Avsändare är ABG Sundal Collier, innehållet är inte skapat av placera.nu:s redaktion.

« Tillbaka

Tempest Security - Securing a strong start

22 maj 2026

<a id="bm-comp-2ecee68c-ee47-4017-bade-4b03c7849c68" name="bm-comp-2ecee68c-ee47-4017-bade-4b03c7849c68" class="BMCustomAnchor"></a><table><tr><td bm-component-id="2ecee68c-ee47-4017-bade-4b03c7849c68" style="vertical-align: top; width:100.000000%;"><ul><li>Q1: +11% sales growth, 3.2% EBITDA margin</li><li>'26e EBITDA up 2%</li><li>Guarding continues to take steps forward</li></ul></td></tr></table><a id="bm-comp-608f2370-3a41-4b27-887d-160c16f2f4ce" name="bm-comp-608f2370-3a41-4b27-887d-160c16f2f4ce" class="BMCustomAnchor"></a><table><tr><td bm-component-id="608f2370-3a41-4b27-887d-160c16f2f4ce" style="vertical-align: top; width:100.000000%;"><h3 class="bm-h3">Starting the year on a positive note</h3><p>Tempest continues to deliver improvements, with Q1 EBITDA coming in 6% above ABGSCe. Guarding grew sales by ~13% (adjusted for the transfer of personal protection into the segment), while EBITDA improved from SEK 8m to SEK 10m. This marks a solid step forward, with focus on stable volume growth and management noting healthy demand within the SOC, a highly scalable area that is interesting for the future. Risk Solutions saw top-line sales decline by SEK 0.5m (adj.) but improved EBITDA from a loss in Q1'25 to a SEK 0.6m profit in Q1'26, driven by Denmark and Sweden. Looking at the broader market, pricing has been a challenge in the security space, but with growing demand for security services, market pricing is improving. As Tempest has scaled, it has established itself as a credible player, which in turn makes bidding for new contracts easier.</p><h3 class="bm-h3">'26e EBITDA up 2%</h3><p>We leave '26e-'28e sales fairly flat and lift '26e EBITDA by 2% due to the good performance and momentum in Guarding. We expect the performance to continue as Tempest maintains its core business focus and continues its efficiency improvements, while Denmark and the UK are delivering better results. Q1 is a seasonally weaker quarter, and now we are entering high season (Q2 and Q3) where we think Tempest can keep the positive momentum.</p><h3 class="bm-h3">Focus on core operations</h3><p>We believe the company took important steps throughout '25, with the divestment of the US and the turnaround in Denmark. There are further efficiencies to be gained from the newly signed contracts in Guarding, as profitability typically increases gradually after the initial start-up period. This is because the additional costs associated with extra hiring decrease, planning and efficiency improve and Tempest can sell additional services that improve profitability.</p></td></tr></table>

Senaste artiklar från alla bolag

Datum Titel Bolag Typ
2026-07-14 Nexam Chemical - Solid Q2, profitability within r... Nexam Chemical Analys
2026-07-14 Nexam Chemical - Record sales and first positive ... Nexam Chemical Analys
2026-07-14 Eastnine - Warsaw to become the largest market Eastnine Analys
2026-07-13 Ascelia Pharma - CRL update Ascelia Pharma Analys
2026-07-13 Medicover - Steady as she goes Medicover Analys
2026-07-13 Arctic Paper - Pulp beats paper Arctic Paper Analys
2026-07-13 Studsvik - Gearing up for the new-build era Studsvik Analys
2026-07-10 StrongPoint - The American dream StrongPoint Analys
2026-07-10 Careium - The pressure valve starting to open Careium Analys
2026-07-10 StrongPoint - Solid Q2 performance StrongPoint Analys
2026-07-10 Careium - Growth's comeback tour continues Careium Analys
2026-07-09 Infrea - Road tripping with Netel Infrea Analys
2026-07-08 Alligo - Softer growth, but margin recovery conti... Alligo Analys
2026-07-08 Qliro - Key earnings drivers intact Qliro Analys
2026-07-07 Nexam Chemical - We expect a firmer sequential qu... Nexam Chemical Analys
2026-07-07 Eastnine - Adding in Warsaw Eastnine Analys
2026-07-06 Ovzon - No Q2 fireworks, but plenty of fuel Ovzon Analys
2026-07-05 StrongPoint - Steady through the transition StrongPoint Analys
2026-07-03 Ascelia Pharma - Complete Response Letter for Orv... Ascelia Pharma Analys
2026-07-03 Fastpartner - Positive development on IFPM guidan... Fastpartner Analys